TXMD
TherapeuticsMD, Inc.
Key Financials
EPS (Diluted)
$-0.05
↑ 73.7%
Total Assets
$37.7M
↓ 3.0%
Total Liabilities
$10.8M
↓ 5.9%
Revenue
$1.8M
↑ 35.3%
Shareholders' Equity
$26.9M
↓ 1.8%
Cash & Equivalents
$5.1M
↑ 16.9%
Operating Income
$-4390000
↑ 7.8%
Gross Profit
$1.3M
↓ 98.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 5/12/2026 | View on SEC |
| 8-K | 5/12/2026 | View on SEC |
| SCHEDULE 13G | 4/6/2026 | View on SEC |
| 10-K/A | 4/1/2026 | View on SEC |
| NT 10-K | 4/1/2026 | View on SEC |
| 8-K | 3/30/2026 | View on SEC |
| 10-K | 3/30/2026 | View on SEC |
| 8-K | 1/21/2026 | View on SEC |
| 4 | 12/29/2025 | View on SEC |
| 8-K | 12/16/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TXMD |
| Company Name | TherapeuticsMD, Inc. |
| CIK | 25743 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | NV |
| Phone | 561-961-1900 |